Accumulating evidence implies that this positive signaling pathway is frequently inactivated in human cancers, as it was shown that expression of DCC and UNC5H is lost during tumor progression, thus, conferring a selective advantage to the tumor cell for survival [3]. This evidence concerns the gene DCC and neoplasm.